Skip to main content
Pediatric delirium is a common though underrecognized and understudied phenomenon in pediatric critical care. The unique combination of the vulnerability and resiliency of children's developing brains makes it imperative that research on prevention, evaluation, treatment, and follow-up of this complication of pediatric medical illness and treatment be vigorously pursued. Although antipsychotics are rarely used for treatment, a small but growing body of research supports the efficacy and short-term safety of using both conventional and atypical antipsychotics. Further understanding of the complex neurophysiology of delirium may lead to more refined treatments. Developmentally valid screening tools will make the assessment and treatment of pediatric delirium more feasible when expert consultation is not available.
The DSM-IV diagnostic criteria for delirium are 1) an acute onset and often fluctuating course of 2) disturbances in arousal and 3) cognition, in the presence of 4) an underlying general medical condition triggering the syndrome (1). Children have been found to have a pattern of symptoms similar to that seen in adults (2).
Clinical subtypes of delirium, recognized in both adult and pediatric patients, are characterized by disturbances in arousal: hyperactive, hypoactive, and mixed delirium (3 5). Hypoactive delirium is underrecognized and has low referral rates because of its less disruptive clinical picture (5 7).
Associated symptoms of delirium include impairments in arousal, attention (thought to be a core symptom), cognition, thought (delusions), language, memory, orientation, perception (hallucinations), sleep-wake cycle, behavior, mood, and affect. Pediatric and adult delirium have similar high rates of impaired alertness, orientation, anxiety, and hallucinations (2). However, pediatric and particularly infant delirium may have subtle developmentally specific symptoms and signs not yet accounted for in available screening measures.
Adult delirium is associated with more self-extubations, longer requirement of mechanical ventilation, inadvertent removal of catheters, prolonged hospital stay, higher health care costs, and increased mortality (6). Adult survivors of delirium have been shown to be at risk for long-term cognitive impairment and posttraumatic stress disorder (PTSD) (6). Children have reported delusional memories of intensive care unit (ICU) experiences, which can become a basis for PTSD later.

Pathophysiology

Children, like elderly patients, have an elevated vulnerability to delirium (7). The “delirium cascade” can originate in any number of pathways associated with systemic illness or iatrogenic intervention: oxygen deprivation, infiamma-tory cytokine release, modification of blood-brain barrier permeability, sick euthyroid syndrome, up-regulation of the hypothalamic-pituitary-adrenal axis, and disruption of intracellular second messenger systems (6, 8). Dysregulation of multiple neurotransmitter systems, particularly of acetylcholine and dopamine, probably plays a role in symptom generation. From research in traumatic brain injury, epilepsy, and meningitis, it is clear that the immature brain has different responses to oxygen deprivation and cytokine release compared to the adult brain (9). Because delirium may represent “end organ damage” of the brain in critical illness, long-term neurocognitive outcome studies in child survivors of untreated delirium are needed.

Evaluation of Delirium in the PICU

Clinical Evaluation

Psychiatric evaluation of the patient in the pediatric intensive care unit (PICU) includes review of the medical history and hospital course, with special attention to the current medication history, pain, itching, and other disturbing medical symptoms; corroborative history, including from multidisciplinary staff and caregivers; and examination of the child.

Screening Instruments

There is a need for screening instruments that could help identify patients with delirium and the subset who need treatment. Some experts have recommended that screening be done during each shift in the PICU, because of the fluctuating course of delirium and the potential for prevention and reversal when treated (10).
The Delirium Rating Scale, the most comprehensive scale used to date, has been shown to have cutoff scores for a pediatric cohort comparable to those for adults (11). However, this scale includes questions that are not applicable to younger children, including self-report of symptoms such as hallucinations and delusions. No validation studies for the Delirium Rating Scale have been conducted with pediatric samples.
The Pediatric Confusion Assessment Method for the ICU (6) is the first validated screening instrument for critically ill children that can be used by staff for the rapid assessment of ventilated and nonventilated patients over age 5. Through the use of yes/no questions, pictures, and hand signals, this instrument allows the evaluation of a child's “inattention” and “disorganized thinking.” Sensitivity and specificity are currently being evaluated in U.S. and European pilot studies.
The Pediatric Anesthesia Emergence Delirium Scale was developed in studies of emergence delirium, which occurs when children are awakening from anesthesia (6, 12). This instrument includes items about the child's eye contact with caregivers, awareness of surroundings, purposeful nature of movements, ability to be consoled, and restlessness. It is validated in children from 19 months to 6 years of age in postoperative settings and is being studied for use in PICU settings. As part of a pediatric delirium diagnostic algorithm, which includes caregiver and multidisciplinary team consensus, the Pediatric Anesthesia Emergence Delirium Scale's focus on neurobehavioral symptoms may make it a useful tool in this younger population and may guide us in developing tools for assessing delirium in the very youngest patients, in whom neurocognitive symptoms are difficult or impossible to assess (10).

Treatment

Sedation in Pediatric Critical Care

Sedative and analgesic agents are integral to the care of critically ill children. Although nonpharmacologic methods, such as intervention by child life specialists and parental presence at the bedside, are routine in the PICU, medications are universally required for tolerance of mechanical ventilation and painful procedures. Fear and anxiety in this stressful environment are also addressed by medications. The medications routinely used in the PICU are presented in Table 1 (13, 14).
TABLE 1. Medications Commonly Used for Sedation in the Pediatric Intensive Care Unit
Drug Class and AgentsEffectsBenefitsAdverse Effects
Opiates: fentanyl, morphine, hydromorphoneAnalgesia, sedation, no amnesiaFentanyl: minimal cardiovascular effects, decrease in sympathetic response, minimal pulmonary vascular resistance effectsFentanyl: rigid chest; morphine: histamine release, hypotension
Benzodiazepines: midazolam, lorazepam, diazepamSedation, amnesia, anxiolysis, seizure control, no analgesiaMidazolam: short-acting; lorazepam and diazepam: seizure controlLorazepam (continuous infusion): lactic acidosis, renal failure, rhabdomyolysis, mental status changes
Barbiturates: thiopental, methohexital, pentobarbitalSedation, seizure control, intracranial pressure controlSeizure control, intracranial pressure controlHypotension, apnea
General anesthetics: propofolSedation, anesthesia, seizure control, no analgesiaShort-acting, seizure control, intracranial pressure controlHypotension, apnea, hypertriglyceridemia, propofol infusion syndromea
Dissociative anesthetics: ketamineAmnesia, analgesiaMaintains heart rate, blood pressure, and respirations; bronchodilationIncreases intracranial pressure, increase in intraocular pressure, negative inotropy, emergence reactions, increase in pulmonary vascular resistance
α2 Adrenergic agonists: dexmedetomidineSedation, anxiolysisSedation, anxiolysisHypotension, hypertension, bradycardia, sinus arrest
a
Propofol infusion syndrome is characterized by metabolic acidosis, dysrhythmias, rhabdomyolysis, and cardiac failure.

Treatment of Pediatric Delirium

When considering treatment for delirium, it is imperative that one consider the risks and benefits of intervention while evaluating 1) the underlying illnesses and treatments, 2) offending agents, such as medications, 3) environmental factors, and 4) indication for antipsychotics. Here we focus on the last three factors.
Potential offending agents include benzodiazepines, opioids, and steroids, as well as other sedatives, including propofol and ketamine. These agents have potentially neurotoxic effects. Recent biochemical research has shown that the toxicity is mediated through complex pathways that may have pro-apoptotic mechanisms as well as through the enhancement of γ-aminobutyric acid (15). These toxic effects have been found to be dependent on dose and duration of exposure, and there is evidence suggesting that they are minimized during exposure to noxious neurostimulation, such as surgery. PICU patients are often exposed to these agents for days, weeks, or months, raising concern about potential long-term neurocognitive harm despite the lack of long-term outcome studies in children (16). Timely dosage tapering minimizes withdrawal symptoms in patients exposed to benzodiazepines, barbiturates, and opioids. Research exploring the association between Akt phosphorylation and anti-apoptotic activity suggests that antipsychotics may be neuroprotective. Coupled with their enhancement of cellular glucose uptake and metabolism, the atypical antipsychotics may make cells more resistant to cellular stress and restore levels of nerve growth factor and brain-derived neurotrophic factor (17). Although this research is preliminary, the potential for neuroprotection and substantial clinical benefits further supports the consideration of antipsychotics.
Environmental stressors do not cause delirium but are an exacerbating factor. They can be minimized by having an active parental (or other familiar caregiver) present at bedside; having familiar, orienting objects in view, such as favorite toys and pictures of home and pets; limiting noxious noise and light; limiting room and staff changes; maintaining approximately normal diurnal schedules; and using one-on-one nursing observation as necessary (5, 18).

Pharmacologic Strategies

Pharmacotherapy may be used to resolve delirium; to reduce agitation, allowing removal of potentially offending agents and improving respiratory management; to limit the time the patient is delirious, decreasing any associated trauma, distress, and potential toxicity; and to reduce the length of hospital stay. The medications recommended are conventional and atypical antipsychotics, which are listed with dosage recommendations in Table 2 (3, 5, 6, 19, 20). There is a nascent pediatric delirium literature indicating safe and rapid resolution of delirium with these agents, even in very young children (2, 3, 5, 6, 21, 22). As in adults, a model of high dopamine for hyperactive delirium and low dopamine/cholinergic imbalance for hypoactive and mixed delirium may suggest the choice of antipsychotic (3). In the case of hyperactive delirium, haloperidol may be more effective because of its narrower targeting of the dopamine D2 receptor. Because of their wider receptor effects, atypical antipsychotics may be more useful in mixed or hypoactive delirium and may lessen the cognitive side effects seen with conventional antipsychotics.
TABLE 2. Profiles of Medications Used in the Treatment of Pediatric Deliriuma
DrugDosingForms AvailableFrequencies of Adverse EffectsbCardiac Effectsc
HaloperidolAge 3–12 years, 0.05–0.15 mg/kg per day divided into two or three doses; dosing interval, 2–12 hoursOral (tablet, solution), intravenous, intramuscular (immediate release and depot), subcutaneous>30%: extrapyramidal side effects; >10%: agitation, insomnia, weight gain, hyperglycemia; >2%: sedation, anticholinergic effects, hyperlipidemia, orthostasis; <2%: blood dyscrasias,d hepatic impairment, seizure, skin reaction; rare: neuroleptic malignant syndrome (highest potency antipsychotic, thus highest risk)Abnormal ECG, <2%; QTc prolongation, >2%; tachycardia, <2%
ChlorpromazineOral: age 6 months–12 years, 2.5–6.0 mg/kg per day, with dosing every 4–6 hours; maximum dosage: age 6 months–5 years, 50 mg/day; age 5–12 years, 200 mg/day. Intramuscular: 2.5–4 mg/kg per day, with dosing every 6–8 hours; maximum, 40 mg/dayOral, intravenous, intramuscular>30%: sedation, anticholinergic effects, orthostasis, weight gain, hyperglycemia, hyperlipidemia, abnormal skin pigmentation; >10%: photosensitivity, other rashes; 2%–10%: extrapyramidal side effects; <2%: agitation, blood dyscrasias,d hepatic impairment, seizuresAbnormal ECG, >30%; QTc prolongation, >2%; tachycardia, >10%
RisperidoneAge 5–16 years, 0.5 mg–2.5 mg/day p.o., divided into two to four doses; maximum dosage: <20 kg, 1 mg/day, 20–45 kg, 2.5 mg/ day, >45 kg, 3 mg/dayOral (tablets, orally disintegrating tablets, solution), intramuscular (depot)>30%: weight gain; >10%: sedation, agitation, extrapyramidal side effects (akathisia/parkinsonism > dystonia), anticholinergic effects, hyperglycemia, hyperlipidemia, orthostasis; <2%: skin reactions, blood dyscrasias,d seizures, hepatic impairmentAbnormal ECG, >2%; QTc prolongation, <2%; tachycardia, >10%
OlanzapineAge 13–17 years, 2.5–10 mg/day; dosing every 12–24 hours; recommended maximum, 20 mg/dayOral (tablets, orally disintegrating tablets), intramuscular>30%: sedation, anticholinergic effects, weight gain, hyperlipidemia, hyperglycemia; >10%: insomnia, agitation; 2%–10%: extrapyramidal side effects (akathisia > dystonia/parkinsonism); >2%: orthostasis, hepatic impairment; <2%: skin reaction, blood dyscrasia, seizureAbnormal ECG, <2%; QTc prolongation, <2%; tachycardia, <2%
QuetiapineAge 10–17 years, 12.5–400 mg; dosing every 12–24 hours (usually 12 hours); recommended maximum, 750 mg/dayOral (tablets; immediate release, extended release)>30%: sedation, anticholinergic effects, hyperglycemia; >10%: agitation, orthostasis, weight gain, hyperlipidemia; >2%: extrapyramidal side effects (akathisia > parkinsonism/dystonia), hepatic impairment; <2%: seizure, skin reaction (no data for rate of blood dyscrasias with quetiapined)Abnormal ECG, <2%; QTc prolongation, <2%; tachycardia, >2%
ZiprasidoneAdults, 5–100 mg/day, usually with dosing every 12 hoursOral, intramuscular>30%: agitation; >10%: sedation, anticholinergic effects, orthostasis; >2%: extrapyramidal side effects, weight gain, hyperglycemia; <2%: seizure, skin reaction; rare: priapism reported in adultsAbnormal ECG, >2%; QTc prolongation, <2%; tachycardia, >2%
AripiprazoleAge 6–17 years, 2–15 mg/day; dosing interval, 12–24 hoursOral (tablets, orally disintegrating tablets, solution), intramuscular>10%: sedation, agitation; 2%–10%: extrapyramidal side effects (akathisia > parkinsonism/dystonia); >2%: anticholinergic effects, weight gain, rash; <2%: hyperglycemia, hyperlipidemia, blood dyscrasia, hepatic impairment (other: dopamine stabilizing, possibly good for hypoactive delirium)Abnormal ECG, <2%; QTc prolongation, <2%; tachycardia, >2%
a
All pediatric recommendations are off-label, not approved by the Food and Drug Administration.
b
Data are for adults.
c
Risk increases with dose.
d
Because of the small risk of leukopenia, discontinue if absolute neutrophil count <1,000.
All antipsychotics carry the risk of QT prolongation, which can lead to torsade de pointes and ultimately sudden death (18, 23, 24). Children with medical illness may have electrolyte abnormalities, infection, hypoxia, or exposure to other cardiotoxic drugs, all of which can increase the likelihood of cardiac arrhythmias with antipsychotic treatment. These factors must be assessed and addressed before antipsychotics are introduced. While most children in PICU settings are already receiving continuous cardiac monitoring, the additional monitoring of QTc, electrolyte levels, and drug interactions during the introduction and course of antipsychotic treatment is prudent. Cessation of antipsychotic treatment must be considered if there is significant QTc prolongation, a QTc >500 msec, new T wave abnormalities, marked bradycardia, or a Brugada pheno-type. Risks may increase with the addition of metabolic inhibitors or other drugs that prolong QTc. Intravenous haloperidol is associated with particular risk for cardiac arrhythmia and should be avoided in high-risk patients whenever possible (18). There are no established clinical guidelines for the use of antipsychotics for delirium in children with preexisting cardiac disease. Each case must be evaluated individually, perhaps with the guidance of pediatric cardiologists, to weigh the risk of arrhythmia against the risks of untreated delirium, such as respiratory compromise and brain anoxia, as in the case presented here.
If cardiac risk is low and the use of antipsychotics is desired, multiple factors may bear on specific drug choice. Intravenous haloperidol has many benefits in cases of reduced gastrointestinal absorption or acute psychomotor agitation threatening the safety of catheters and ventila-tory support because it can be rapidly administered and absorbed. It also has minimal effects on blood pressure, respiration, and heart rate; a low sedative effect; and few anticholinergic side effects. In less acute situations and when oral medication is possible, atypical antipsychotics are preferred (5, 18). The choice of atypical agent can be based on side effect profile. The most serious side effects to consider are those of cardiac toxicity. Current limited data indicate that cardiac risks are similar across all atypical antipsychotics except that there may be less QTc prolongation with aripiprazole. Once the decision has been made to use an atypical agent, one can consider need for sedation, appetite stimulation/weight gain, nausea control, or glycemic control to identify the best drug. Table 2 describes drug profiles in detail.

Conclusions

The treatment of infants and young children with delirium is a new frontier in pediatrics and psychosomatic medicine, with limited information about assessment tools, best practices, and potential side effects of treatment. Clinical practitioners should be aware, however, that there are potential developmental consequences to untreated delirium in this population and consider intervention when appropriate.

Footnote

Received Nov. 10, 2009; revision received Jan. 27, 2010; accepted March 18, 2010

References

1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM-IV-TR). Washington, DC, American Psychiatric Association, 2000
2.
Turkel SB, Tavare CJ: Delirium in children and adolescents. J Neuropsychiatry Clin Neurosci 2003; 15:431–435
3.
Karnik NS, Joshi SV, Paterno C, Shaw R: Subtypes of pediatric delirium: a treatment algorithm. Psychosomatics 2007; 48:253–257
4.
Leentjens AF, Schieveld JN, Leonard M, Lousberg R, Verhey FR, Meagher DJ: A comparison of the phenomenology of pediatric, adult, and geriatric delirium. J Psychosom Res 2008; 64:219–223
5.
Schieveld JN, Leroy PL, van Os J, Nicolai J, Vos GD, Leentjens AF: Pediatric delirium in critical illness: phenomenology, clinical correlates, and treatment response in 40 cases in the pediatric intensive care unit. Intensive Care Med 2007; 33:1033–1040
6.
Smith HA, Fuchs DC, Pandharipande PP, Barr FE, Ely EW: Delirium: an emerging frontier in the management of critically ill children. Crit Care Clin 2009; 25:593–614, x
7.
Martini DR: Commentary: the diagnosis of delirium in pediatric patients. J Am Acad Child Adolesc Psychiatry 2005; 44:395–398
8.
Maldonado JR: Pathoetiological model of delirium: a comprehensive understanding of the neurobiology of delirium and an evidence-based approach to prevention and treatment. Crit Care Clin 2008; 24:789–856, ix
9.
Potts MB, Koh SE, Whetstone WD, Walker BA, Yoneyama T, Claus CP, Manvelyan HM, Noble-Haeusslein LJ: Traumatic injury to the immature brain: inflammation, oxidative injury, and iron-mediated damage as potential therapeutic targets. NeuroRx 2006; 3:143–153
10.
Schieveld JN, van der Valk JA, Smeets I, Berghmans E, Wassenberg R, Leroy PL, Vos GD, van Os J: Diagnostic considerations regarding pediatric delirium: a review and a proposal for an algorithm for pediatric intensive care units. Intensive Care Med 2009; 35:1843–1849
11.
Turkel SB, Braslow K, Tavare CJ, Trzepacz PT: The Delirium Rating Scale in children and adolescents. Psychosomatics 2003; 44:126–129
12.
Sikich N, Lerman J: Development and psychometric evaluation of the Pediatric Anesthesia Emergence Delirium Scale. Anesthesiology 2004; 100:1138–1145
13.
Carroll CL, Krieger D, Campbell M, Fisher DG, Comeau LL, Zucker AR: Use of dexmedetomidine for sedation of children hospitalized in the intensive care unit. J Hosp Med 2008; 3:142–147
14.
Tobias JD: Sedation and analgesia in the pediatric intensive care unit. Pediatr Ann 2005; 34:636–645
15.
Jevtovic-Tudorovic V: Neurotoxicity of commonly used general anaesthetics: is it possible? in Anaesthesia, Pain, Intensive Care, and Emergency Medicine: APICE: Proceedings of the 20th Postgraduate Course in Critical Care Medicine, Trieste, Italy, November 18–21, 2005. Trieste, Milken Publishers, 2006
16.
Loepke AW, McGowan FX, Soriano SG: Con: The toxic effects of anesthetics in the developing brain: the clinical perspective. Anesth Analg 2008; 106:1664–1669
17.
Pillai A, Terry AV, Mahadik SP: Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 2006; 82:95–106
18.
Breitbart W, Alici-Evcimen Y: Why off-label antipsychotics remain first-choice drugs for delirium. Curr Psychiatr 2007; 10:49–63
19.
Bexchlibnyk-Butler K, Virani A: Antipsychotics, in Clinical Handbook of Psychotropic Drugs for Children and Adolescents. Edited by, Bexchlibnyk-Butler K, Virani A. Cambridge, Mass, Hogrefe and Huber Publishers, 2004, pp 90–136
20.
Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W: A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005; 13:529–534
21.
Brown RL, Henke A, Greenhalgh DG, Warden GD: The use of haloperidol in the agitated critically ill pediatric patient with burns. J Burn Care Rehabil 1996; 17:34–38
22.
Schieveld JN, Leentjens AF: Delirium in severely ill young children in the pediatric intensive care unit (PICU). J Am Acad Child Adolesc Psychiatry 2005; 44:392–394
23.
Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M: A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24:62–69
24.
Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350:1013–1022

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1172 - 1177
PubMed: 20889664

History

Received: 10 November 2009
Revision received: 27 January 2010
Accepted: 18 March 2010
Published online: 1 October 2010
Published in print: October 2010

Authors

Details

Gabrielle H. Silver, M.D.
From the Department of Child Psychiatry, New York–Presbyterian/Weill Cornell Medical Center.
Julia A. Kearney, M.D.
From the Department of Child Psychiatry, New York–Presbyterian/Weill Cornell Medical Center.
Martha C. Kutko, M.D.
From the Department of Child Psychiatry, New York–Presbyterian/Weill Cornell Medical Center.
Abraham S. Bartell, M.D.
From the Department of Child Psychiatry, New York–Presbyterian/Weill Cornell Medical Center.

Notes

Address correspondence and reprint requests to Dr. Silver, Department of Child Psychiatry, New York–Presbyterian/Weill Cornell Medical Center, 525 East 68th St., Box 140, New York, NY 10065; [email protected] (e-mail).

Funding Information

All authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share